Victrix Investment Advisors Takes Position in McKesson Co. (NYSE:MCK)

Victrix Investment Advisors purchased a new position in shares of McKesson Co. (NYSE:MCK - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,454 shares of the company's stock, valued at approximately $829,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Norges Bank bought a new position in shares of McKesson in the fourth quarter valued at approximately $1,200,361,000. Farallon Capital Management LLC acquired a new position in shares of McKesson during the 4th quarter valued at $348,044,000. Marshall Wace LLP raised its stake in shares of McKesson by 59,720.3% in the 4th quarter. Marshall Wace LLP now owns 358,922 shares of the company's stock worth $204,553,000 after buying an additional 358,322 shares in the last quarter. Leigh Baldwin & CO. LLC bought a new stake in shares of McKesson in the 4th quarter worth $182,861,000. Finally, Proficio Capital Partners LLC acquired a new stake in shares of McKesson in the fourth quarter valued at $178,397,000. 85.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other McKesson news, CEO Brian S. Tyler sold 8,961 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $597.99, for a total transaction of $5,358,588.39. Following the completion of the sale, the chief executive officer now directly owns 60,664 shares in the company, valued at $36,276,465.36. This represents a 12.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 543 shares of the company's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $726.51, for a total value of $394,494.93. Following the transaction, the chief accounting officer now owns 1,972 shares of the company's stock, valued at approximately $1,432,677.72. This trade represents a 21.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.11% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on MCK. Cfra Research lowered McKesson from a "moderate buy" rating to a "hold" rating in a report on Friday, April 4th. Wells Fargo & Company lifted their price objective on shares of McKesson from $641.00 to $691.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Mizuho increased their target price on shares of McKesson from $630.00 to $690.00 and gave the company a "neutral" rating in a research note on Thursday, April 3rd. Wall Street Zen lowered shares of McKesson from a "strong-buy" rating to a "buy" rating in a research report on Wednesday. Finally, Morgan Stanley upped their price target on McKesson from $642.00 to $745.00 and gave the company an "overweight" rating in a report on Wednesday, April 2nd. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, McKesson has an average rating of "Moderate Buy" and a consensus target price of $686.69.

McKesson Price Performance

McKesson stock traded down $8.43 during trading hours on Thursday, hitting $710.30. The company had a trading volume of 599,391 shares, compared to its average volume of 916,584. The firm's fifty day moving average is $687.71 and its 200-day moving average is $631.12. The firm has a market capitalization of $88.87 billion, a P/E ratio of 32.52, a price-to-earnings-growth ratio of 1.29 and a beta of 0.53. McKesson Co. has a fifty-two week low of $464.42 and a fifty-two week high of $731.70.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $10.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.83 by $0.29. McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. The business had revenue of $90.82 billion during the quarter, compared to analyst estimates of $94 billion. During the same period last year, the company earned $6.18 earnings per share. McKesson's quarterly revenue was up 18.9% compared to the same quarter last year. Analysts anticipate that McKesson Co. will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Monday, June 2nd will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Monday, June 2nd. McKesson's dividend payout ratio is presently 10.99%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.